Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as a promising therapy for patients with obesity-related MHD and HFpEF [8], [9]. The gene discussed is SLC5A2; the disease is obesity due to melanocortin 4 receptor deficiency.